Trial Profile

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Sep 2025 According to Lundbeck A/S media release, data from this study will be presented in an oral presentation by Richard Lipton on 13 September at the 2025 International Headache Congress, taking place in Sao Paulo (Sept 10-13).
14 Sep 2023 According to H. Lundbeck A/S media release, the company announced the data from this study at the International Headache Congress (IHC) 2023 in Seoul, Korea.
14 Sep 2023 Primary endpoint (Change From Baseline in the Number of Monthly Migraine Days (MMDs) at Month 1 (Weeks 1-4)) has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com